Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services

Ahmedabad, India – June 4, 2025: Veeda Lifesciences, a global contract research organization (CRO) today announced a strategic partnership with Mango Sciences, a Boston based AI-driven healthcare data company. The collaboration aims to address critical challenges in clinical trial patient recruitment and diversity by leveraging Mango Sciences’ proprietary AI-enabled analytics platform, Querent™. The collaboration will equip Veeda with an AI technology platform for conducting clinical trials, leveraging its network of hospital sites across India. Veeda aims to drive innovation in oncology clinical trials and improve trial outcomes. This partnership allows Veeda to become a tech-enabled, and AI-driven drug development CRO for oncology clinical trials.

“By merging Veeda’s scientific expertise with Mango Sciences’ AI technology and hospital network, we propose to address one of the challenges in clinical trials: timely recruitment of patients that meet the protocol inclusion exclusion criteria,” said Dr. Mahesh Bhalgat, Group CEO and Managing Director, Veeda Clinical Research Limited (Veeda Lifesciences). “Our partnership aims to make Veeda an AI-driven drug development organization in oncology, with access to cancer patients. This strategic alliance will enable Veeda to provide diversity to trials in line with the expectations of regulators and pharmaceutical companies.”

Veeda aims to save capital and have representative participation from ‘non-Caucasian’ populations through Mango Sciences’ AI platform. By leveraging data analytics, the partnership aims to improve speed of executing clinical trials, including better patient matching, more efficient trial designs, and improved monitoring and analysis throughout the trial process. This technology proposes to reduce the time and cost associated with clinical trials, ensuring efficient and effective research and development.

Highlighting the role of AI technology in improving oncology patient outcomes, Dr. Mohit Misra, Founder & CEO of Mango Sciences, said, “Our roadmap includes leveraging the use of Large Language Models (LLMs) for clinical trials, driving both operational efficiencies, and identifying the right drug for the right patient perfecting the Querent™ Cohort Builder with LLMs, and implementing Generative AI for Real-World Evidence.

About Veeda Lifesciences:

Veeda Lifesciences (Veeda Clinical Research Limited) platform providing a comprehensive portfolio of services across various stages of drug development value chain to support small and medium biotech and pharmaceutical companies with capabilities ranging from non-clinical and pre-clinical development to clinical pharmacology and clinical trials across different modalities. Visit: https://veedalifesciences.com/

About Mango Sciences:

Mango Sciences is a healthcare technology company dedicated to transforming patient care through advanced data analytics and solutions. Founded by industry veterans with extensive experience in healthcare, life sciences, and data analytics, Mango Sciences is driven by a passion for improving patient representation and access to comprehensive healthcare. Visit: https://mangosciences.com/

Disclaimer: 

Veeda Clinical Research Limited (the “Company”) is proposing, subject to receipt of requisite approvals, market conditions and other considerations, a public issue of its equity shares in the near future and is in the process of filing a draft red herring prospectus with the Securities and Exchange Board of India. This document is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and will contain detailed information about the Company and management, as well as financial statements. The Company does not intend to register any part of the offering in the United States.